AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
03 June 2024 - 11:15PM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), today announced that
Thomas K. Equels, MS JD, Chief Executive Officer of AIM will
participate in the Virtual Investor Lunch Break Series on
Wednesday, June 5, 2024 at 12:00 PM ET.
As part of the event, Mr. Equels will provide a
corporate overview and business outlook. In addition to the
prepared remarks, interested parties will have the opportunity to
submit questions live during the event. Mr. Equels will answer as
many questions as possible in the time allowed.
A live video webcast of the presentation will be available on
the Events page of the Company’s website (aimimmuno.com). A webcast
replay will be available two hours following the live presentation
and will be accessible for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From May 2024 to Jun 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Jun 2023 to Jun 2024